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Zusammenfassung
Hintergrund: Herpes-simplex-Virus (HSV)-Infektionen
sind häufig. Sehr selten kommt es hingegen zu einer
HSV-induzierten Hepatitis, die unbehandelt in der Regel
tödlich verläuft. Fallbeschreibung: Ein 68-jähriger Patient
mit einem lokal fortgeschrittenen und inoperablen Öso-
phaguskarzinom stand unter kombinierter Radiochemo-
therapie nach Induktionschemotherapie. Nach insgesamt
9 Behandlungswochen verstarb er an einem fulminanten
Leberversagen unklarer Ätiologie. Post mortem fand sich
überraschenderweise eine schwergradige HSV-Infektion
des Ösophagus sowie eine HSV-assoziierte nekrotisie-
rende Hepatitis. Schlussfolgerung: Bei diesem immun-
kompromittierten Patienten postulieren wir eine HSV-
 assoziierte Ösophagitis, die zu einer Virämie und einer
fulminanten Hepatitis geführt hat. Insbesondere bei im-
munkompromittierten Patienten sollte eine HSV-Hepatitis
differentialdiagnostisch in Betracht gezogen werden,
wenn eine anikterische Hepatitis mit stark erhöhten
 Serumtransaminasewerten vorliegt. Eine Leberbiopsie
liefert den schnellsten Nachweis einer HSV-Hepatitis.
Falls eine Leberbiopsie wegen einer schweren Koagulo-
pathie nicht möglich ist, sollte ein DNA-Nachweis im Blut
mittels Polymerase-Kettenreaktion-Technik versucht
 werden. Noch vor Erhalt des Resultates ist bei Vorliegen
des typischen biochemischen Profils eine baldige empi -
rische Behandlung mit Aciclovir zu erwägen.
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Summary
Background: Herpes simplex virus (HSV) infections are
frequent. However, HSV hepatitis is rare and may lead to
a life-threatening condition. Case Report: A 68-year-old
patient with a locally advanced and inoperable eso -
phageal carcinoma was treated with induction chemo -
therapy and combined chemoradiation. After a total of 
9 weeks of treatment, he developed fulminant liver fail-
ure of unknown origin and died a few days later. Surpris-
ingly, the post mortem examination revealed an HSV in-
fection of the esophagus and an HSV-associated necroti-
sizing hepatitis. Conclusion: In this immunocompro-
mised patient, we postulate an HSV-associated eso-
phagitis that led to viremia and fulminant hepatitis.
 Especially in immunocompromised hosts, HSV hepatitis
should be considered in the differential diagnosis in
 patients with anicteric hepatitis and marked elevation of
transaminases. A liver biopsy is the quickest and most
definitive diagnostic tool to diagnose HSV hepatitis. If
this is not possible because of severe coagulopathy,
polymerase chain reaction for HSV DNA should be per-
formed. Awaiting diagnosis, a prompt empirical treat-
ment with acyclovir has to be discussed in case of a char-
acteristic biochemical profile.
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Introduction
Herpes simplex virus (HSV) is one of the most common
 causes of viral infection. The two main subtypes, HSV-1 and
HSV-2, are known for their ability to cause a variety of illness-
es, including mucocutaneous infections, infections of the cen-
tral nervous system and an occasional infection of visceral or-
gans [1]. HSV esophagitis may result from direct extension of
oro-pharyngeal HSV infection into the esophagus or may
occur by reactivation and spread of HSV along the vagus
nerve to the esophageal mucosa. Host factors clearly influence
the rates of infection and reactivation. Immunocompromised
patients have both more frequent and more severe infections
and reactivations.
Case Report
A 68-year-old man was diagnosed with an adenocarcinoma of the distal
esophagus. Staging was done by endoscopy, endoscopic ultrasound and
computed tomography (CT) scan and revealed stage uT3 uN1 cM0.
 Because of the extensive mediastinal lymphadenopathy, the patient was
assessed to be inoperable. He was registered in a multicenter phase II
 clinical trial for advanced inoperable esophageal cancer and received
2 cycles of induction chemotherapy with docetaxel 75 mg/m2 and cisplatin
75 mg/m2 every 3 weeks. Restaging CT showed a regression of the tumor
and the lymph node metastases. On day 43 the planned definitive
chemoradiation was initiated: According to the protocol, the chemoradia-
tion consisted of 59.4 Gy in 33 dose fractions of 1.8 Gy with concomitant
weekly docetaxel of 15 mg/m2 and cisplatin of 25 mg/m2.
At 4 weeks after start of chemoradiotherapy the patient rapidly devel-
oped weakness, fatigue and loss of appetite without pain or dysphagia. He
was admitted to the hospital with a decreased performance status, a tem-
perature of 37.9 °C and mild hepatomegaly. Laboratory analysis revealed
an anicteric hepatitis with pronounced elevation of serum aminotrans-
ferases (aspartate aminotransferase (AST) 9226 U/l (9–45 U/l), alanine
aminotransferase (ALT) 5355 U/l (8–63 U/l)) and lactate dehydrogenase
(LDH >12,000 U/l (240–480 U/l)), but normal bilirubin. Furthermore, it
showed pancytopenia (leukocytes 0.8 × 109/l, hemoglobin 112 g/l, throm-
bocytes 15 × 109/l), a severe renal insufficiency with a creatinine clearance
of 12 ml/min and a coagulopathy. The results of serological tests for he-
patitis B and C virus were negative.
The patient died of acute failure of the liver and the kidney within 2 days,
despite full supportive care.
Macroscopic, Microscopic and Immunohistochemical Findings
The autopsy revealed massive necrosis of the liver (organ 1730 g); the left
lobe was more severely affected than the right one (fig. 1). Light mi-
croscopy showed confluent and bridging necrosis without evidence of re-
generation. A number of hepatocytes were multinucleated and exhibited
a homogeneous pale chromatin, indicative of an HSV infection. Immuno-
histochemistry revealed nuclear and cytoplasmic positivity of the hepato-
cytes for HSV (fig. 2; antigen: HSV I and II; species: rabbit; dilution: predi-
luted; source: Cell Marque, Hot Springs, AR, USA). The squamous ep-
ithelium, adjacent to the necrotic adenocarcinoma of the lower esophagus
(diameter 4 cm; tumor stage: ypT3 ypN1 ypM0; tumor regression grade 
3 (range 1–5) according to Mandard et al. [2]) showed ballooning degen-
eration and multinucleated keratinocytes with homogeneous pale chro-
matin, consistent with an HSV infection (fig. 3).
Discussion
Our patient presented with normal bilirubin and very high
 levels of transaminases and LDH. This characteristic pattern
of liver function abnormalities can be found in approximately
90% of cases with fulminant herpes simplex hepatitis and is
described as ‘anicteric hepatitis’. Most of the case studies have
demonstrated marked elevations of transaminases with AST 
> ALT (up to 1000-fold). Leukopenia is also a common find-
ing in HSV hepatitis [3–7]. In our case, the leukopenia and the
thrombopenia are likely due to myelosuppression caused by
the chemotherapy with docetaxel and cisplatin. Moreover,
both substances accumulated in view of the severe hepatic 
and renal insufficiency and possibly aggravated the myelosup-
pression.
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Fig. 1. Macroscopy of the liver: Massive necrosis in fatal herpetic hepatitis
that progressed to liver failure. The dark zones represent massive necrosis
with  adjacent congested liver. The left lobe is more severely affected than the
right one.
 
Fig. 2. Microscopy
of the liver (immuno -
peroxidase staining
directed against 
HSV I and II, × 200):
Necrotic and intact
zones and hepato-
cytes with nuclear
and cytoplasmic posi-
tivity for HSV.
 
Fig. 3. Microscopy
of the esophagus
(hematoxylin/eosin, 
× 400): Squamous epi -
thelium with balloon-
ing degeneration and
multinucleated kera -
tinocytes with homo-
geneous pale chro-
matin.
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In immunocompetent patients, infection by HSV can cause a
mild, self-limited hepatitis. Acute hepatitis with severe liver
failure is a rare manifestation of HSV infection and is usually
fatal. Most of these patients have an underlying condition as-
sociated with impaired host defense. This includes organ trans-
plantation, cytostatic therapy, prolonged treatment with corti-
costeroids, malignancy or disorders of the skin integrity such
as burns [6, 8]. Impaired cell-mediated immunity is thought to
be responsible for HSV dissemination, although the specific
mechanism is unknown [6]. Therefore, HSV hepatitis should
be suspected in immunocompromised hosts with anicteric
 hepatitis and marked elevation of transaminases, fever and
leukopenia. Mucocutaneous lesions are not necessarily part of
the diagnosis, as over 40% of patients will not have identifi-
able oral or genital lesions or a prior history of HSV infection
[3, 6, 7].
Physicians need to be aware of the clinical abnormalities. If
direct hepatotoxicity by drugs, hepatitis viruses or sepsis can
be excluded, confirmatory testing for HSV should be per-
formed. As viremia is an important factor in the pathogenesis
of disseminated HSV infections in immunocompromised
 patients, detection of HSV viremia should be tried. This can
be done with a simple blood culture method by observing cy-
topathic effects and confirmation by indirect fluorescent
staining with monoclonal antibody to HSV [8]. Polymerase
chain reaction (PCR) has emerged as a rapid and sensitive
diagnostic tool for diagnosis of HSV disease by detection of
HSV DNA. Routinely, it is used on viral culture, cere-
brospinal fluid and biopsy specimens. Reports could show
PCR detection of HSV in the plasma and peripheral blood
mononuclear cells [9].  Furthermore, real-time PCR is in 
development [10, 11].
Biopsy including immunohistochemical staining is the gold
standard test in this situation [7, 12]. The histology is charac-
terized by areas of cellular necrosis with little inflammation
and hepatocytes with either eosinophilic inclusion bodies or
the more characteristic pattern of homogeneous pale chro-
matin [4–6]. However, as in our case, liver biopsy is frequently
not possible because of severe coagulopathy. In individual
cases, transjugular liver biopsy with appropriate plasma sup-
port can be considered [13].
In view of the high mortality and the fact that HSV hepatitis is
one of the few causes of fulminant hepatic failure for which
potentially effective therapy is available, HSV hepatitis has to
be considered early in any case of unexplained fulminant he-
patitis. If there are no obvious risk factors for other forms of
hepatitis, we suggest to perform a liver biopsy or PCR for
HSV in the peripheral blood prior to an empirical therapy
with acyclovir. Only a rapid start of a specific therapy can
 improve the serious prognosis of this illness [3, 5, 7, 12, 14].
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